A carregar...
Overall Safety of Ospemifene in Postmenopausal Women from Placebo-Controlled Phase 2 and 3 Trials
Objective: To evaluate the safety of daily oral ospemifene 60 mg, estrogen agonist/antagonist, used to treat moderate-to-severe dyspareunia due to postmenopausal vulvovaginal atrophy, which is part of genitourinary syndrome of menopause. Methods: Post hoc analysis of safety data (treatment-emergent...
Na minha lista:
| Publicado no: | J Womens Health (Larchmt) |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Mary Ann Liebert, Inc.
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5771532/ https://ncbi.nlm.nih.gov/pubmed/29064335 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/jwh.2017.6385 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|